中国组织工程研究 ›› 2012, Vol. 16 ›› Issue (6): 1067-1070.doi: 10.3969/j.issn.1673-8225.2012.06.026

• 干细胞基础实验 basic experiments of stem cells • 上一篇    下一篇

急性淋巴细胞白血病患者骨髓细胞中CCL2 mRNA的表达**★

 

王晓桃,唐荣芳,唐爱林,聂宇薇,刘 健,莫东华
  

  1. 桂林医学院附属医院血液内科,广西壮族自治区桂林市  541001
  • 收稿日期:2011-07-03 修回日期:2011-08-09 出版日期:2012-02-05 发布日期:2012-02-05
  • 作者简介:王晓桃★,女,1975年生,湖南省永州市人,汉族,2004年中山大学毕业,硕士,副主任医师,主要从事恶性血液病的临床与基础研究。wxttjl@126.com
  • 基金资助:

    桂林市科学研究与技术开发计划项目(20110119-1-12)、广西卫生厅计划课题(Z2011200)。

Expression of chemokine receptor 2 mRNA in bone marrow cells of acute lymphocytic leukemia patients  

Wang Xiao-tao, Tang Rong-fang, Tang Ai-lin, Nie Yu-wei, Liu Jian, Mo Dong-hua   

  1. Department of Hematology, Affiliated Hospital of Guilin Medical College, Guilin  541001, Guangxi Zhuang Autonomous Region, China
  • Received:2011-07-03 Revised:2011-08-09 Online:2012-02-05 Published:2012-02-05
  • About author:Wang Xiao-tao★, Master, Associate chief physician, Department of Hematology, Affiliated Hospital of Guilin Medical College, Guilin 541001, Guangxi Zhuang Autonomous Region, China wxttjl@126.com
  • Supported by:

     Project of Scientific Research and Technology Development of Guilin, No. 20110119-1-12*; Health Department Planning Project of Guangxi Zhuang Autonomous Region, No. Z2011200*

摘要:

背景:临床工作中希望能够根据骨髓CCL2表达对急性淋巴细胞白血病患者进行危险分层和预后判断。
目的:观察急性淋巴细胞白血病患者骨髓细胞中CCL2 mRNA的表达情况。
方法:初诊50例急性淋巴细胞白血病患者为实验组,30例非血液肿瘤患者为对照组。初诊急性淋巴细胞白血病患者化疗2个疗程后按疗效分为完全缓解组43例,未完全缓解组7例。实验抽取研究对象骨髓5 mL,采用半定量聚合酶链反应法检测CCL2 mRNA表达。
结果与结论:①初诊急性淋巴细胞白血病组CCL2 mRNA表达水平明显高于对照组(P < 0.05);完全缓解组CCL2 mRNA水平明显低于未完全缓解组(P < 0.01);完全缓解组治疗后CCL2 mRNA表达水平明显低于治疗前(P < 0.01)。未完全缓解组治疗2个疗程后CCL2 mRNA表达水平无明显下降(P > 0.05)。②前B-急性淋巴细胞白血病患者骨髓CCL2 mRNA表达水平明显高于普通B及T系急性淋巴细胞白血病患者(P < 0.05)。初诊时白细胞≥50×109 L-1急性淋巴细胞白血病患者CCL2 mRNA表达水平明显高于白细胞<10×109 L-1及10×109 L-1≤白细胞<50×109 L-1组(P < 0.05),10×109 L-1≤白细胞<50×  109 L-1组明显高于白细胞<10×109 L-1组(P < 0.01)。结果表明急性淋巴细胞白血病患者骨髓细胞能分泌CCL2,骨髓CCL2 mRNA表达水平与患者初诊时的白细胞计数及免疫分型有一定的关系,在一定程度上能反映患者的近期疗效。

关键词: 急性淋巴细胞白血病, 趋化因子受体, CCL2, 短期疗效, 骨髓细胞

Abstract:

BACKGROUND: In clinical practice, the expression of chemokine receptor 2 (CCL2) in bone marrow cells is hoped to be used in hazardous classification and prognosis estimation of acute lymphocytic leukemia patients.
OBJECTIVE: To investigate the expression of CCL2 mRNA in bone marrow cells of patients with acute lymphocytic leukemia.
METHODS: Fifty patients with newly diagnosed ALL were selected as experimental group, and thirty patients without hematological tumor were taken as control group. After treatment, the experimental group was divided into complete remission (CR) group (43 cases) and incomplete remission group (7 cases) according to the efficacy. 5 mL bone marrow from each case was extracted in order to detect the CCL2 mRNA expression by semi-quantitative polymerase chain reaction. 
RESULTS AND CONCLUSION: CCL2 mRNA expression in the experimental group was significantly higher than that in the  control group (P < 0.05). CCL2 mRNA expression in the CR group was significantly lower than that in the incomplete remission group (P < 0.01). CCL2 mRNA expression in the CR group after treatment was decreased than before (P < 0.01). CCL2 mRNA expression in the incomplete remission group before treatment was not obviously decreased compared with that after 2 courses of treatment (P > 0.05). CCL2 mRNA expression in acute lymphocytic leukemia patients with immune subtype pre-B was higher than with immune subtype common B and T (P < 0.05). CCL2 mRNA expression in patients with white blood cells≥50×109/L was higher than patients with white blood cells <10×109/L and 10×109/L≤ white blood cells < 50×109/L (P < 0.05), the 10×109/L≤ white blood cells < 50×109/L group was higher than the white blood cells < 10×109/L group (P < 0.01). It is indicated that the bone marrow of acute lymphocytic leukemia patients can secrete out CCL2, bone marrow levels of CCL2 mRNA are related to the count of white blood cells at diagrosis and the immune subtype. The levels of CCL2 mRNA can reflect the short short-term outcomes in some degree.

中图分类号: